Copyright healthcareradius
Glenmark Pharmaceuticals, USA (Glenmark) has announced the upcoming launch of 8.4 per cent Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial. Glenmark’s 8.4 per cent Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, 8.4 per cent Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (Abbott) NDA – 019443. Glenmark will begin distribution in November 2025. According to IQVIA® sales data for the 12 months ending August 2025, the 8.4 per cent Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) market achieved annual sales of approximately USD 63.8 million. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are pleased to announce the expansion of our injectable portfolio to include the upcoming launch of 8.4 per cent Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial, which further reinforces our dedication to bring quality and affordable alternatives to market to patients in need.” Glenmark’s 8.4 per cent Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is only approved for the indication(s) listed in Glenmark’s approved label. Market includes brand and all available therapeutic equivalents. Also Read: Glenmark Pharma to launch Ropivacaine injection for pain management in the US Note: IQVIA® data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for the indications listed in Glenmark’s approved label and is not marketed for all RLD indications.
